Poster: Drug/Disease Modelling - Other Topics Archives - PAGE Meeting (Population Approach Group Europe)

Opemalirsen antisense oligonucleotide targeting the APOL1 mRNA provide dose-dependent APOL1 reduction in plasma

Thursday 7 May, 2026

Objectives APOL1-mediated kidney disease (AMKD) is associated with toxic gain of function variants in people of African ancestry with the…

INTEGRATED POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE MODELING OF ENLICITIDE IN HYPERCHOLESTEROLEMIA PATIENTS SUPPORTS CLINICAL DOSE RECOMMENDATION ACROSS PATIENT SUBGROUPS

Thursday 7 May, 2026

Introduction: Despite the well-established cardiovascular benefit of LDL-cholesterol (LDL-C) lowering, real-world use of PCSK9-targeted therapies remains limited, in part due…

Is regrowth of Mycobacterium tuberculosis always a sign of phenotypical resistance? A model-based approach to interpret drug instability and the implications for potency estimation in time-kill assays.

Thursday 7 May, 2026

Introduction:The observed regrowth of Mycobacterium tuberculosis (Mtb) in vitro is often attributed to the emergence of phenotypical resistance or relapse-associated…

Advancing Antimalarial Therapy Using PBBM: Impact of Physiology and Formulation on Artesunate Absorption

Thursday 7 May, 2026

INTRODUCTION Successful treatment of uncomplicated malaria relies on oral therapies, yet the absorption of antimalarial agents such as artesunate remains…

Model-based meta-analysis (MBMA) of effect of biologics on FEV1 in severe asthma

Thursday 7 May, 2026

Objectives: Asthma patients exhibit significant heterogeneity in disease presentation driven by involvement of type I (allergic) and type II (eosinophilic)…

MODEL-INFORMED APPROACHES FOR PEDIATRIC TYPE 2 DIABETES EVIDENCE GENERATION: INSIGHTS FROM A MODEL-BASED LONGITUDINAL HBA1C META-ANALYSIS FROM EMA MARKETING AUTHORIZATION APPLICATIONS

Thursday 7 May, 2026

Introduction: The efficacy of a new medicinal drug product indicated for the treatment or prevention of Type 2 Diabetes Mellitus…

Mechanistic Modelling of SARS-CoV-2 Viral Dynamics and Antiviral Effects to Link Viral Exposure with Clinical Outcomes

Thursday 7 May, 2026

Introduction: To evaluate antiviral effectiveness, the PANORAMIC trial, a large open-label platform study, was conducted in outpatients at increased risk…

A Modular PBPK-QSP Platform for Renal–Cardiovascular Pharmacology: Simulating RAAS-Targeted Therapies and Drug-Induced Kidney Injury

Thursday 7 May, 2026

Objectives Mechanistic modeling offers a unique opportunity to integrate complex renal and cardiovascular physiology with pharmacological interventions. Dogs have historically…

QUANTITATIVE DIFFERENCES IN TRENDS OF INFLAMMATORY BIOMARKERS IN PREGNANT AND POSTPARTUM INDIVIDUALS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE

Thursday 7 May, 2026

Introduction: Pregnancy involves major physiological changes that can alter dynamics of biomarkers commonly used in pre-pregnancy[1–3]. Among these, C-reactive protein…

Translational Modeling Based on a Semi-Mechanistic Target-Mediated Drug Disposition (TMDD) Approach

Thursday 7 May, 2026

Objectives: ABO21009 is a humanized IgG1 monoclonal antibody targeting human CD45RC, currently developed for the treatment of rheumatoid arthritis. The…